We are live on
!
Find out more
5VM
5AM Venture Management Portfolio holdings
AUM
$288M
1-Year Est. Return
313.93%
This Fund
S&P 500
This Quarter
Est. Return
+22.99%
1 Year Est. Return
+313.93%
3 Year Est. Return
+546.33%
5 Year Est. Return
+596.42%
10 Year Est. Return
–
AUM
$288M
AUM Growth
-$72.3M
(-20%)
Cap. Flow
-$93.3M
Cap. Flow
% of AUM
-32.42%
Top 10 Holdings %
Top 10 Hldgs %
85.57%
Holding
20
New
–
Increased
–
Reduced
1
Closed
4
Avg Time Held
8.7
quarters
Top 10 Avg Time Held
3.6
quarters
Top 20 Avg Time Held
7
quarters
Top Buys
No buys this quarter
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Erasca
ERAS
|
+$56.4M |
| 2 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$23.1M |
| 3 |
GH Research
GHRS
|
+$8.05M |
| 4 |
Surrozen
SRZN
|
+$3.19M |
| 5 |
Rallybio
RLYB
|
+$2.62M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
MapLight Therapeutics
MPLT
$426M
| $34M | 11.83% |
950,011
| – | – |
2025 Q4
2 quarters
|
|
2
Tyra Biosciences
TYRA
$1.27B
| $32.9M | 11.42% |
1,029,298
| – | – |
2023 Q3
11 quarters
|
|
3
Entrada Therapeutics
TRDA
$167M
| $29.9M | 10.37% |
4,056,379
| – | – |
2021 Q4
18 quarters
|
|
4
Pharvaris
PHVS
$2.11B
| $27.6M | 9.58% |
797,600
| – | – |
2022 Q2
16 quarters
|
|
5
CAMP4 Therapeutics
CAMP
$205M
| $25.6M | 8.91% |
5,869,091
| – | – |
2024 Q4
6 quarters
|
|
6
Artiva Biotherapeutics
ARTV
$297M
| $22.8M | 7.93% |
2,353,304
| – | – |
2024 Q3
7 quarters
|
|
7
Tectonic Therapeutic
TECX
$413M
| $20.9M | 7.24% |
606,660
| – | – |
2024 Q2
8 quarters
|
|
8
Zentalis Pharmaceuticals
ZNTL
$225M
| $19.1M | 6.65% |
3,947,913
| – | – |
2023 Q2
12 quarters
|
|
9
Celldex Therapeutics
CLDX
$2.21B
| $18.5M | 6.43% |
497,270
| – | – |
2023 Q2
12 quarters
|
|
10
EyePoint Inc
EYPT
$255M
| $15M | 5.22% |
1,050,000
| – | – |
2024 Q2
8 quarters
|
|
11
Biohaven
BHVN
$1.68B
| $11M | 3.82% |
738,972
| – | – |
2023 Q4
10 quarters
|
|
|
12
Surrozen
SRZN
$273M
| $7.04M | 2.45% |
271,250
-116,250
| -30% | -$3.19M |
2025 Q1
5 quarters
|
|
13
Skye Bioscience
SKYE
$6.69M
| $6.71M | 2.33% |
1,210,220
| – | – |
2024 Q2
8 quarters
|
|
14
ALX Oncology
ALXO
$127M
| $6.33M | 2.2% |
3,057,325
| – | – |
2026 Q1
1 quarter
|
|
15
Protara Therapeutics
TARA
$152M
| $5.23M | 1.82% |
1,369,782
| – | – |
2024 Q4
6 quarters
|
|
16
Silence Therapeutics
SLN
$566M
| $5.23M | 1.82% |
476,200
| – | – |
2024 Q1
9 quarters
|
|
|
CNTA
17
DELISTED
Centessa Pharmaceuticals
CNTA
| – | – |
-580,945
| Closed | -$23.1M | – |
|
|
18
Erasca
ERAS
$5.11B
| – | – |
-3,485,971
| Closed | -$56.4M | – |
|
|
19
GH Research
GHRS
$1.28B
| – | – |
-572,665
| Closed | -$8.05M | – |
|
|
20
Rallybio
RLYB
$89M
| – | – |
-291,788
| Closed | -$2.62M | – |
|
Similar funds
TA
APW
RCS
FH
IAMOG
MP
OL
CFG
5AM Venture Management's Q2 2026 Portfolio in Review
As of Q2 2026, 5AM Venture Management held 20 positions worth $288M, down 20% from $360M the previous quarter. Its ten largest holdings account for 86% of the portfolio.
5AM Venture Management withdrew a net $93.3M in Q2 2026, closing 4 positions and reducing 1 holding. Its most notable exit was Erasca, an estimated $56.4M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
- 5AM Venture Management's biggest Q2 2026 reduction was Surrozen, cutting an estimated $3.19M.
- 5AM Venture Management fully exited Erasca in Q2 2026, selling an estimated $56.4M.
- 5AM Venture Management's ten largest holdings make up 86% of its $288M portfolio in Q2 2026.
- 5AM Venture Management opened 0 new positions and closed 4 in Q2 2026.
- 5AM Venture Management's portfolio value fell 20% quarter-over-quarter to $288M.
Based on 5AM Venture Management's 13F filing for Q2 2026, filed 14 Aug 2026.